Hsbc Holdings PLC Boosts Holdings in Embecta Corp. (NASDAQ:EMBC)

Hsbc Holdings PLC raised its position in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 322.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,517 shares of the company's stock after purchasing an additional 63,768 shares during the period. Hsbc Holdings PLC owned 0.14% of Embecta worth $1,728,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Barclays PLC increased its holdings in Embecta by 41.1% in the 3rd quarter. Barclays PLC now owns 97,930 shares of the company's stock worth $1,381,000 after acquiring an additional 28,523 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Embecta in the fourth quarter worth about $209,000. Bank of New York Mellon Corp increased its stake in shares of Embecta by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company's stock worth $14,155,000 after purchasing an additional 4,769 shares in the last quarter. Amundi raised its position in shares of Embecta by 161.2% in the fourth quarter. Amundi now owns 32,287 shares of the company's stock valued at $655,000 after purchasing an additional 19,925 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in Embecta by 41.4% in the 4th quarter. Prudential Financial Inc. now owns 154,580 shares of the company's stock worth $3,192,000 after buying an additional 45,290 shares during the period. 93.83% of the stock is owned by hedge funds and other institutional investors.

Embecta Price Performance

Shares of EMBC traded down $0.04 during midday trading on Wednesday, hitting $12.18. 49,472 shares of the company traded hands, compared to its average volume of 453,023. Embecta Corp. has a one year low of $10.27 and a one year high of $21.48. The firm has a market cap of $707.78 million, a P/E ratio of 12.17, a PEG ratio of 0.78 and a beta of 1.24. The stock has a 50-day moving average of $12.50 and a 200-day moving average of $15.81.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. Sell-side analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were given a dividend of $0.15 per share. The ex-dividend date was Friday, February 28th. This represents a $0.60 annualized dividend and a yield of 4.93%. Embecta's payout ratio is presently 60.00%.

Insiders Place Their Bets

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the completion of the sale, the director now owns 36,133 shares of the company's stock, valued at $591,858.54. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.42% of the company's stock.

Analyst Ratings Changes

Separately, Mizuho began coverage on shares of Embecta in a report on Thursday, April 10th. They set a "neutral" rating and a $15.00 target price on the stock.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.